Welcome to the December, 2008 issue of Pharma Marketing News.
To better understand the impact of this code on the pharmaceutical industry, Pharma Marketing News surveyed readers between July 10, 2008 and August 7, 2008, and collected comments from pharma-focused blogs and bulletin boards. This article is a summary of the PMN survey results and opinions of experts, bloggers, and anonymous commentators.
Medical journals may soon become the pharmaceutical industry's newest physician marketing partner. This article summarizes some of the pros and cons of FDA's Good Reprint Practices Guidance and presents preliminary results of a reader survey on the topic.
This article, written by a marketer with firsthand experience, provides an overview of the pharmaceutical markets and promotional practices in India.
This article is a review of an industry conference presentation that focused focused on leveraging eDetailing for effective closed-loop marketing campaigns.
Should free drug samples be banned? The new PhRMA Code on Interactions with Healthcare Professionals bans free pens and out-of-office lunches, but it doesn't ban samples. Many sales consider free drug samples an important marketing tactic that they can employ to gain access to physicians. In 2005, the pharmaceutical industry distributed more than $18 billion worth of drug samples. But critics are concerned that drug samples increase costs, raise questions about the appropriateness of treatment choices, and create real or perceived conflicts of interest in the medical profession.
This article highlights five tips from OnDemandIQ designed to help Small Pharma focus and prioritize their sales teams on their most important goals -- improving efficiency and boosting sales.
Welcome to the October, 2008 issue of Pharma Marketing News.
As everyone knows by now, Pfizer caved in to withering criticism from Congress and the Pharma BlogospereT and pulled the Jarvik Lipitor ads. 'Oh what a tangled web we weave, When first we practise to deceive!'
Possibly the most important political change facing the pharmaceutical industry in 2006 is who will be the new FDA Commissioner. Various stakeholders -- including executives and staffers working within the pharmaceutical industry, agents and vendors to the industry, healthcare professionals, members of the general public, and staffers within government health agencies -- have divergent opinions on who should be the commissioner and why. This article summarizes the results of a recent survey of such stakeholders.